Woman who is pregnant or lactating or has a positive pregnancy test at screening. If a woman has a positive pregnancy test, further evaluation may be conducted to rule out ongoing pregnancy to allow the patient to be eligibleXx_NEWLINE_xXPositive test for latent TB at Screening (Quantiferon test)Xx_NEWLINE_xXWomen who are breastfeeding or pregnant as evidenced by a positive pregnancy test within 14 days of first dose.Xx_NEWLINE_xXFemale patients who are both lactating and breastfeeding, who have a positive serum pregnancy test during screening, or who plan to become pregnant while in the trial or within 90 days after receiving protocol-directed treatmentXx_NEWLINE_xXPregnancy tests for females of childbearing potential are required; must be serum at screening and the post treatment safety assessment visit; a positive urine pregnancy test must be confirmed by a serum pregnancy test and a pelvic ultrasound (US); a pelvic US does not need to be repeated with each cycle unless the treating physician thinks it is necessary to do soXx_NEWLINE_xXFemale subjects who have positive serum pregnancy test taken within 14 days of initiation of study treatment.Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after contraception and until the termination of gestation, confirmed by a positive hCG laboratory testXx_NEWLINE_xXFemale patients who are nursing or have a positive pregnancy test during screening are not eligibleXx_NEWLINE_xXA WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of study treatment.Xx_NEWLINE_xXHas a positive pregnancy test within 72 hours before the first dose of study therapyXx_NEWLINE_xXPositive serum pregnancy testXx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory testXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXA positive pregnancy test will exclude patients from the study in addition to excluding them from receiving standard therapyXx_NEWLINE_xXFemale patients who are breast feeding or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXWomen with a positive pregnancy testXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXPregnancy (positive serum or urine ?HCG test) or breast-feedingXx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.Xx_NEWLINE_xXFemale patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXWomen of childbearing potential (WOCBP), who:\r\n* Are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 8 weeks after cessation of study drug, or\r\n* Have a positive pregnancy test at baseline, or\r\n* Are pregnant or breastfeedingXx_NEWLINE_xXWomen who\r\n* Are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study therapy\r\n* Have a positive pregnancy test at baseline\r\n* Are pregnant or breastfeedingXx_NEWLINE_xXFemale patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period.Xx_NEWLINE_xXMen and women who:\r\n* Are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug, or women who:\r\n** Have a positive pregnancy test at baseline, or\r\n** Are pregnant or breastfeedingXx_NEWLINE_xXDONOR: Females with a positive pregnancy testXx_NEWLINE_xXA WOCBP who has a positive serum pregnancy test within 72 hours prior to enrollment on studyXx_NEWLINE_xXIn female, a negative pregnancy test if experiencing menstrual periods.Xx_NEWLINE_xXFemale patients who are both lactating and breastfeeding or have positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drugXx_NEWLINE_xXFemale subjects with reproductive potential must agree to undergo a medically supervised pregnancy test prior to starting study drug. The first pregnancy test will be performed at screening (within 7 days prior to first study drug administration). A pregnancy test should also be performed on the day of the first study drug administration and confirmed negative prior to dosing as well as before dosing on Day 1 of all subsequent cyclesXx_NEWLINE_xXPatients who are pregnant or lactating, plan to get pregnant, or have a positive serum pregnancy test prior to randomization.Xx_NEWLINE_xXThe HBV DNA test will be performed only for patients who have a positive HBcAb testXx_NEWLINE_xXFemale patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drug (if applicable)Xx_NEWLINE_xXPregnant or need to breast feed during the study period (negative serum pregnancy test required)Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXWomen with a positive pregnancy test at enrollment or prior to administration of study medication.Xx_NEWLINE_xXFemales who are breastfeeding or pregnant at Screening or Baseline. A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 h before the first dose of study drug.Xx_NEWLINE_xXPositive screening EBV antibody titer on screening testXx_NEWLINE_xXFemale subjects who are pregnant or lactating, including females with a positive pregnancy test at screening.Xx_NEWLINE_xXWomen with a positive pregnancy testXx_NEWLINE_xXWomen with a positive pregnancy test or lactating.Xx_NEWLINE_xXParticipants with borderline pregnancy tests at Screening must have a serum pregnancy test ? 3 days later to document continued lack of a positive result.Xx_NEWLINE_xXWomen with a positive pregnancy test on enrollment or prior to investigational product administrationXx_NEWLINE_xXPositive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug. Women who are lactating and breastfeeding are not eligible.Xx_NEWLINE_xXIs pregnant (confirmed by positive serum pregnancy test) or lactatingXx_NEWLINE_xXFemale patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drugXx_NEWLINE_xXFemales who are both lactating and breastfeeding or who have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drugXx_NEWLINE_xXPositive pregnancy test for women of childbearing ageXx_NEWLINE_xXWomen with a positive pregnancy test on enrollment or prior to investigational product administrationXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test suggestive of pregnancy and not as a tumor marker during the screening period; if pregnancy is tested positive, treating physician will further investigate if the patient is pregnant or not; treating physician may consider repeating the serum beta-hCG at next follow up visit or refer patient to obstetrical/gynecological (OB/GYN) for further evaluationXx_NEWLINE_xXIn female, a negative pregnancy test if experiencing menstrual periodsXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXWomen who are breast-feeding or pregnant as evidenced by positive urine pregnancy test done within 72 hours of first dosingXx_NEWLINE_xXFOCBP must have a negative pregnancy test within 7 days prior to registration\r\n* Note: FOCBP will have to have repeat pregnancy test within 24 hours of starting nivolumab, scheduled for cycle 1 day 1Xx_NEWLINE_xXPositive pregnant status confirmed by serum or urine pregnancy testXx_NEWLINE_xXWomen who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy testXx_NEWLINE_xXWomen who are pregnant, which includes women with a positive pregnancy test at enrollment or prior to the administration of study medication, or breastfeeding are not allowed on studyXx_NEWLINE_xXFemale patients of childbearing potential who have a positive blood or urine pregnancy test at screeningXx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by positive b-hCG laboratory testXx_NEWLINE_xXFemale patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXnEGFR positiveXx_NEWLINE_xXWomen with a positive pregnancy test.Xx_NEWLINE_xXWomen with a positive pregnancy testXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXPositive pregnancy test in a femaleXx_NEWLINE_xXPositive serum pregnancy testXx_NEWLINE_xXPositive serum pregnancy testXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.Xx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory testXx_NEWLINE_xXA positive urine pregnancy test during the screening period; women who are two years post-menopausal, or who have had a tubal ligation or a partial or full hysterectomy will not be subject to a urine pregnancy testXx_NEWLINE_xXPositive pregnancy test for women of childbearing ageXx_NEWLINE_xXHave a positive direct Coombs testXx_NEWLINE_xXWomen who:\r\n* Are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug, or\r\n* Have a positive pregnancy test at baseline, or\r\n* Are pregnant or breastfeedingXx_NEWLINE_xXWomen of childbearing potential (WOCBP), defined above, who:\r\n* Are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 26 weeks after cessation of study drug, or\r\n* Have a positive pregnancy test at baseline, or\r\n* Are pregnant or breastfeedingXx_NEWLINE_xXPositive serology for HBV defined as a positive test for HBsAg; in addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HepB DNA test will be performed and if positive the subject will be excludedXx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory testXx_NEWLINE_xXWomen who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy testXx_NEWLINE_xXWomen of childbearing potential (WOCBP) who: (a) are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for up to 26 weeks after cessation of study drug, or (b) have a positive pregnancy test at baseline, or (c) are pregnant or breastfeedingXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXPregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory testXx_NEWLINE_xXPositive pregnancy test in a female patient of childbearing potential defined as not post-menopausal for twelve months or no previous surgical sterilizationXx_NEWLINE_xXPositive Hepatitis C test result at screening or within 3 months prior to first dose of study treatment.Xx_NEWLINE_xXFemale patients who are lactating, breastfeeding, or have a positive pregnancy testXx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test.Xx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcG laboratory test.Xx_NEWLINE_xXPositive pregnancy test (for pre-menopausal women)Xx_NEWLINE_xX220 Females with a positive pregnancy test.Xx_NEWLINE_xXFemale patients who are lactating or have a positive pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drugXx_NEWLINE_xXPregnant or or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL)Xx_NEWLINE_xXThe subject is pregnant, as defined by a presumptive sign of pregnancy such as missed menses or a positive pregnancy testXx_NEWLINE_xXWomen with a positive pregnancy test on enrollment or prior to investigational product administrationXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXDONOR: Females with a positive pregnancy testXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day 1 before first dose of study drug, if applicableXx_NEWLINE_xXSubjects who have a positive pregnancy test, are pregnant, lactating or have reproductive potential and not practicing an effective means of contraceptionXx_NEWLINE_xXagree to take a pregnancy test prior to starting study medication and throughout the study participation.Xx_NEWLINE_xXPregnant patients or patients who are breast feeding. Subjects capable of pregnancy (post menarche and not post-menopausal, defined as over 12 months since final menstrual period) must have a negative pregnancy test within 7 days prior to first dose.Xx_NEWLINE_xXWomen who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy testXx_NEWLINE_xXFor women: Must be surgically sterile, post-menopausal, or compliant with a medically approved contraceptive regimen during and for 3 months after the treatment period; must have a negative serum or urine pregnancy test and must not be nursing.Xx_NEWLINE_xXFemales who are pregnant, breastfeeding or who have a positive pregnancy test at screening or Day 1Xx_NEWLINE_xXNegative serum pregnancy test at screening (sensitivity of at least 25 mIU/mL); (Note that the screening serum pregnancy test can be used as the test prior to starting IP in the pharmacokinetics phase if it is performed within the 72-hour timeframe), andXx_NEWLINE_xXWomen who are pregnant or breast feeding; women with a positive pregnancy test on enrollment or prior to study drug administrationXx_NEWLINE_xXFemales who are pregnant, breastfeeding or who have a positive pregnancy test at screening or Day 1.Xx_NEWLINE_xXPregnant or lactating females; serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days (with a confirmatory urine pregnancy test within 7 days prior to study treatment start)Xx_NEWLINE_xXWomen who are breastfeeding or pregnant as evidenced by positive serum pregnancy testXx_NEWLINE_xXFemale participants who are lactating and breast feeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.Xx_NEWLINE_xXWomen who are pregnant (including positive pregnancy test at enrollment or prior to study drug administration) or breast-feedingXx_NEWLINE_xXFemale patients who are lactating or have a positive blood pregnancy test during the screening periodXx_NEWLINE_xXWomen with a positive pregnancy test on enrollment or prior to investigational product administrationXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day 1 before first dose of study drug, if applicableXx_NEWLINE_xXFemales patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drugXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXKnown pregnancy, nursing women or positive pregnancy testXx_NEWLINE_xXWomen who are breastfeeding or pregnant as evidenced by positive serum pregnancy testXx_NEWLINE_xXFemale patients must be surgically sterile, post-menopausal (for at least 1 year), or have negative results from a pregnancy test performed as follows:\r\n* At screening, on a serum sample obtained within 14 days prior to the first study drug administration, and\r\n* Prior to dosing, on a urine sample obtained on day 1 of treatment if it has been > 7 days since obtaining the serum pregnancy test resultXx_NEWLINE_xXWomen with a positive pregnancy test at enrollment or prior to administration of study medicationXx_NEWLINE_xXPregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (greater than 5 mIU/mL)Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXPregnant nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL)Xx_NEWLINE_xXPositive pregnancy test in a femaleXx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period.Xx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.Xx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXWomen of childbearing potential (WOCBP), defined above who:\r\n* Are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 3 months after cessation of study drug, or\r\n* Have a positive pregnancy test at baseline, or\r\n* Are pregnant or breastfeedingXx_NEWLINE_xXSexually active WOCBP must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab; if the pregnancy test is positive, the patient must not receive ipilimumab and must not be enrolled in the studyXx_NEWLINE_xXPositive pregnancy testXx_NEWLINE_xXWomen who are breast feeding or pregnant as evidenced by positive serum pregnancy test.Xx_NEWLINE_xXWomen with a positive pregnancy test on enrollment or prior to investigational product administrationXx_NEWLINE_xXPhase 1b subject has a positive drug or alcohol urine test at screening visit.Xx_NEWLINE_xXA WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of study treatmentXx_NEWLINE_xXFemale patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drugXx_NEWLINE_xXFemale patients who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drugXx_NEWLINE_xXPregnant (positive pregnancy test)Xx_NEWLINE_xXFCBP must have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to initiating lenalidomide; the first pregnancy test must be performed within 10-14 days before day 1 cycle 1 and the second pregnancy test must be performed within 24 hours of day 1 cycle 1; the subject may not receive lenalidomide until the treating investigator has verified that the results of these pregnancy tests are negative, and must agree to ongoing pregnancy tests; for patients already on Revlimid, continuation of current testing schedule is permitted as long as it is not interrupted during the transition to CRd therapyXx_NEWLINE_xXFemale subject who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day 1 before first dose of study drug, if applicableXx_NEWLINE_xXFemale research participants >= 10 years of age or post-menarchal must not be pregnant (confirmed by serum or urine pregnancy test within 1 week of study enrollment) or breastfeedingXx_NEWLINE_xXWomen with a positive pregnancy testXx_NEWLINE_xXPositive serum or urine pregnancy testXx_NEWLINE_xXWomen of childbearing potential (WOCBP), defined above who:\r\n* Are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 26 weeks after cessation of study drug, or\r\n* Have a positive pregnancy test at baseline, or\r\n* Are pregnant or breastfeeding\r\nNOTE: before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab or HDI; if the pregnancy test is positive, the patient must not receive ipilimumab or HDI and must not be enrolled in the studyXx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 of any cycleXx_NEWLINE_xXThe patient is pregnant (confirmed by urine or serum pregnancy test) or lactatingXx_NEWLINE_xXWomen of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 8 weeks after cessation of study drug, or have a positive pregnancy test at baseline, or are pregnant or breastfeedingXx_NEWLINE_xXWomen with a positive pregnancy test on enrollment or before investigational product administrationXx_NEWLINE_xXHepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HGsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded.Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum or urine pregnancy test during the Screening period.Xx_NEWLINE_xXSubject has positive test result at the screening visit for one or more of the following:Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXPregnancy (positive serum ?-HCG) or breastfeeding.Xx_NEWLINE_xXPregnancy (positive serum or urine pregnancy test) or breast feedingXx_NEWLINE_xXPremenopausal and postmenopausal (amenorrheic for less than 12 months) women with either a positive or no pregnancy test (serum or urine) at baseline within 7 days study enrollment; postmenopausal women who are amenorrheic for more than 12 months do not require pregnancy testXx_NEWLINE_xXWomen with a positive pregnancy testXx_NEWLINE_xXPregnancy or breast-feeding (women of childbearing potential, any female who has experienced menarche and who has not undergone surgical sterilization or is not post-menopausal with a positive serum pregnancy test)Xx_NEWLINE_xXPregnancy or breast-feeding (women of childbearing potential, any female who has experienced menarche and who has not undergone surgical sterilization or is post-menopausal with a positive serum pregnancy testXx_NEWLINE_xXAnd have a negative blood pregnancy test at the time of screeningXx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (at screening or baseline).Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before administration of the first dose of study drug.Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXHave a negative serum pregnancy test (? -hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study therapy. This applies even if the subject practices true abstinence* from heterosexual contact.Xx_NEWLINE_xXWomen who are pregnant (including positive pregnancy test at enrollment or prior to study drug administration) or breastfeedingXx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive pregnancy test during the Screening period.Xx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive pregnancy test during the Screening period.Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patient who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test within 72 hours of initiation of treatment, or a positive urine pregnancy test on day 1 before first dose of study drug, if applicable; pregnancy testing is not required for postmenopausal or surgically sterilized womenXx_NEWLINE_xXWomen of childbearing potential (WOCBP) who:\r\n* Are unwilling or unable to use acceptable methods of contraception to avoid pregnancy for their entire study period and for at least 5 months after cessation of study drug, or\r\n* Have a positive pregnancy test at baseline, or\r\n* Are pregnant or breastfeedingXx_NEWLINE_xXPositive pregnancy test.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) who:\r\n* Are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 23 weeks after cessation of study drug, or\r\n* Have a positive pregnancy test at baseline, or\r\n* Are pregnant or breastfeedingXx_NEWLINE_xXWoman who is pregnant or lactating or has a positive pregnancy test at screening. If a woman has a positive pregnancy test, further evaluation may be conducted to rule out ongoing pregnancy to allow the patient to be eligible.Xx_NEWLINE_xXKnown HIV positive and positive screening pregnancy test or is breast-feeding.Xx_NEWLINE_xXPregnant (positive pregnancy test) or lactatingXx_NEWLINE_xXSubjects in their reproductive age who are breast feeding or have a positive pregnancy testXx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of alisertib.Xx_NEWLINE_xXPatient is pregnant as confirmed by positive serum or urine pregnancy test within 14 days prior to enrollmentXx_NEWLINE_xXAll WOCBP MUST have a negative pregnancy test within 7 days prior to first receiving investigational product; if the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the studyXx_NEWLINE_xXFemale participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day 1 before first dose of study drug, if applicableXx_NEWLINE_xXPregnant or nursing (lactating) women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory testXx_NEWLINE_xXPregnant (positive pregnancy test) and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown.Xx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day 1 before first dose of study drug, if applicableXx_NEWLINE_xXWomen who are pregnant (confirmed by positive pregnancy test) or lactatingXx_NEWLINE_xXInadequate organ functions, positive pregnancy test.Xx_NEWLINE_xXFemale subjects who have positive serum pregnancy test taken within 14 days of study treatmentXx_NEWLINE_xXFemale participants who are both lactating and breastfeeding, or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before the first dose of study drugXx_NEWLINE_xXWomen with a positive pregnancy test on enrollment or prior to investigational product administrationXx_NEWLINE_xXPregnancy (positive serum or urine pregnancy test) or breast feeding;Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) who:\r\n* Are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 8 weeks after cessation of study drug, or\r\n* Have a positive pregnancy test at baseline, or\r\n* Are pregnant or breastfeedingXx_NEWLINE_xXSexually active WOCBP must use an effective method of birth control during the course of study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab; if the pregnancy test is positive, the patient must not receive ipilimumab and must not be enrolled in the studyXx_NEWLINE_xXWomen with a positive pregnancy test at study entry.Xx_NEWLINE_xXPositive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded.Xx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to enrollment; if urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\r\n* If a pregnancy occurs, the study doctor must be notified; the study doctor should notify the study sponsor as well as Amgen of the pregnancy, discuss any follow-up with the subject (and/or his partner), and ask for information on the pregnancy outcome; the patient should be asked if she wishes to consent to follow up through the Amgen pregnancy surveillance program\r\n* If the female partner is already pregnant when the male subject begins treatment with talimogene laherparepvec, he must refrain from any sort of sexual activity that could expose his partner or the unborn baby to talimogene laherparepvec through semen, or wear a latex condom during sexual activity while receiving treatment with talimogene laherparepvec and for at least 3 months after the last talimogene laherparepvec administrationXx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory testXx_NEWLINE_xXWomen of childbearing potential (WOCBP), defined above, who:\r\n* Are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 26 weeks after cessation of study drug, or\r\n* Have a positive pregnancy test at baseline, or\r\n* Are pregnant or breastfeedingXx_NEWLINE_xXPregnancy confirmed by pregnancy test / Lactating women;Xx_NEWLINE_xXFemale participants who are lactating and breast-feeding or a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before the first dose of study drug.Xx_NEWLINE_xXSatisfactory results of screening safety labs, serum testosterone test and drug testXx_NEWLINE_xXPatient is a woman with a positive urine or serum pregnancy test within 3 days prior to study drug administration, is breast-feeding, or is planning to conceive children within the projected duration of the study treatmentXx_NEWLINE_xXCurrently pregnant (assessed by serum pregnancy test)Xx_NEWLINE_xXWomen who are pregnant at time of enrollment; pregnancy will be assessed at enrollment using urine pregnancy testXx_NEWLINE_xXNegative se rum pregnancy test and not planning to be pregnant in the next 3 monthsXx_NEWLINE_xXA positive pregnancy test, currently pregnant or planning to become pregnant in the next three monthsXx_NEWLINE_xXAll pre-menopausal women will require a urine qualitative pregnancy test to exclude pregnancy; pregnant women will be excluded from the studyXx_NEWLINE_xXNot pregnant (confirmed by a pregnancy test)Xx_NEWLINE_xXPregnancy: All female patients < 55 years old (yo) will be administered a urine pregnancy test prior to enrollmentXx_NEWLINE_xXPregnant or breastfeeding women; positive pregnancy test within 7 days of starting treatmentXx_NEWLINE_xXPatients who are pregnant or breastfeeding; patients will be asked about the possibility of pregnancy; a pregnancy test will be obtained for those patients who have been sexually active without using birth control since their last menstrual period; pregnancy status can be confirmed using any of the following: pregnancy test, prior hysterectomy, tubal ligation, use of intra-uterine device (IUD) or Depo-Provera, or if the woman is beyond childbearing ageXx_NEWLINE_xXFemale participant of childbearing age must not be pregnant (confirmed by serum or urine pregnancy test within 1 week of eligibility) or lactatingXx_NEWLINE_xXFemale subjects who are surgically sterilized or who have not experienced menses for at least two years are not required to have a pregnancy testXx_NEWLINE_xXPatients who are pregnant are excluded; pre-menopausal women must have a negative pregnancy test; patients that are post-menopausal, or that have had a hysterectomy do not need to have a pregnancy testXx_NEWLINE_xXSubject is pregnant (documented by a positive pregnancy test according to hospital standard practices) or is actively breast-feeding.Xx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive pregnancy test (urine or serum)Xx_NEWLINE_xXPatients with baseline (at start leukemia treatment) infection, defined as patients with fever and known positive cultures at the time of registration; or chest or sinus computed tomography with findings suggestive of pneumonia or sinusitis; or one positive galactomannan test >= 1 or two positive galactomannan test >= 0.5 to 1Xx_NEWLINE_xXSatisfactory results of screening safety labs, urine pregnancy test and drug testXx_NEWLINE_xXAll female patients of childbearing potential including those who are within 1 year of last menstrual period will be required to take a pregnancy test during screening, enrollment and at week 0, 4, 8 and 12Xx_NEWLINE_xXWomen who are able to become pregnant must have a confirmed negative pregnancy test result prior to enrollment; women >= 50 years of age who have not had a menstrual period in the past year; and women who have had a hysterectomy, both ovaries removed, or a tubal ligation; will not be required to have a pregnancy testXx_NEWLINE_xXA positive urine pregnancy test during the screening period. Women who are one year post-menopausal, or who have had a tubal ligation or a partial or full hysterectomy will not be subject to a urine pregnancy test.Xx_NEWLINE_xXPatient is a woman with a positive serum pregnancy test at screening, is pregnant, breast-feeding, or is planning to conceive children within the projected duration of the study treatmentXx_NEWLINE_xXWomen with an abnormal pap test, positive human papillomavirus (HPV) test or any history of cervical dysplasiaXx_NEWLINE_xXA positive urine pregnancy test during the screening period; women who are two years post-menopausal, or who have had a tubal ligation or a partial or full hysterectomy will not be subject to a urine pregnancy testXx_NEWLINE_xXPositive pregnancy test on day of surgeryXx_NEWLINE_xXA positive urine pregnancy test during the screening period; women who are two years post-menopausal, or who have had a tubal ligation or a partial of full hysterectomy will not be subject to a urine pregnancy testXx_NEWLINE_xXWomen who are able to become pregnant must have a confirmed negative pregnancy test result prior to enrollment; women who are >= 60 years old or who have had a hysterectomy, both ovaries removed, or a tubal ligation will not be required to have a pregnancy testXx_NEWLINE_xXPositive pregnancy test or breastfeeding of patient or donor (women of childbearing age only)Xx_NEWLINE_xXPositive urine drug test at screening visitXx_NEWLINE_xXPositive pregnancy testXx_NEWLINE_xXPositive pregnancy test (women of childbearing age only)Xx_NEWLINE_xXPositive pregnancy test or nursing (women of childbearing age only)Xx_NEWLINE_xXAgree to abstain from breastfeeding during study participation and for at least 90 days after the last dose of IP. Note that the screening serum pregnancy test can also be used as the test prior to starting IP (Investigational Product) if it is performed within the 72-hour timeframe.Xx_NEWLINE_xXWomen who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy testXx_NEWLINE_xXPositive pregnancy testXx_NEWLINE_xXCurrently known to be pregnant; (Note that urine pregnancy tests will be performed prior to the DXA and pQCT studies; positive pregnancy test at that time would preclude participation; a positive pregnancy test will be immediately reported to the patient’s primary oncology provider)Xx_NEWLINE_xXPositive serum pregnancy test in WOCBPXx_NEWLINE_xXFemale patients who are lactating or have a positive pregnancy test during the screening periodXx_NEWLINE_xXDetermination of pregnancy status: Female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to each set of [18F]FLT and [18F] Fluciclovine PET scans; a negative test will be necessary for such patients to undergo research PET imagingXx_NEWLINE_xXPregnant or lactating women: pregnant women are excluded from this study because the effects of [18F] FAZA in pregnancy are not known. A urine or serum pregnancy test will be performed before accrual after informed consent is obtained.Xx_NEWLINE_xXIn female patients, negative pregnancy test with no plans to become pregnant during the duration of the studyXx_NEWLINE_xXPositive pregnancy testXx_NEWLINE_xXPositive serum pregnancy test for femalesXx_NEWLINE_xXFemale patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to the research PET scans; the serum pregnancy test must be performed within 48 hours prior to the initial research PET imaging; a negative test will be necessary for such patients to undergo research PET imagingXx_NEWLINE_xXDetermination of pregnancy status: female patients that are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to each set of multi-tracer PET scans; a negative test will be necessary for such patients to undergo research PET imagingXx_NEWLINE_xXPositive urine pregnancy test or currently breast-feedingXx_NEWLINE_xXPositive urine pregnancy test or currently breast feedingXx_NEWLINE_xXPatient Volunteers/Contrast Enhancement Sub-group: Positive urine pregnancy test or currently breast-feedingXx_NEWLINE_xXPregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excludedXx_NEWLINE_xXA pregnancy test will be used to determine eligibility in appropriate patientsXx_NEWLINE_xXFemale patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans; the serum pregnancy test must be performed within 48 hours prior to research PET imaging; a negative test will be necessary for such patients to undergo research PET imagingXx_NEWLINE_xXPregnant or lactating female, a serum pregnancy test will be performed within 2 weeks or less before the date of the FCH PET/CT scan in all women capable of becoming pregnantXx_NEWLINE_xXFemales who are pregnant as confirmed by a positive serum or urine pregnancy test or are breastfeeding.Xx_NEWLINE_xXBreastfeeding or pregnant; serum pregnancy test will be conductedXx_NEWLINE_xXDetermination of pregnancy status: female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans; the serum pregnancy test must be performed within 48 hours prior to research PET imaging; a negative test will be necessary for such patients to undergo research PET imagingXx_NEWLINE_xXFemale patients who are lactating or have a positive serum pregnancy test during the screening periodXx_NEWLINE_xXPregnant or breastfeeding - if the subject is female, the investigator will provide a urine pregnancy test at no cost to the subject; the subject will take the pregnancy test immediately before participating in this studyXx_NEWLINE_xXPositive Hemoglobin-Solubility (e.g., SickleDex™ or equivalent) test.Xx_NEWLINE_xXPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.Xx_NEWLINE_xXFemale with a positive pregnancy test or who is planning to become pregnant during the duration of the study.Xx_NEWLINE_xXPositive test for HbsAg, or positive test for HBcAb (unless serology is positive due to recent intravenous immunoglobulin therapy). HBcAb positivity will be allowed if HBsAb is present.Xx_NEWLINE_xXIs female participant who are lactating and breast-feeding or a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before the first dose of study drug.Xx_NEWLINE_xX